No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population

Molecular Biology Reports

Volumn 41, Issue 7, 2014, Pages 4631-4638

  Giannakopoulou, E ^a   Ragia, G ^a   Kolovou, V ^b   Tavridou, A ^a,c   Tselepis, A D ^d   Elisaf, M ^d   Kolovou, G ^b   Manolopoulos, V G ^a,c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c Academic General Hospital Alexandroupolis   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atorvastatin; Hypercholesterolemia; Pharmacogenomics; Response; Simvastatin; SLCO1B1

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TRIACYLGLYCEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PYRROLE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN;

ADULT; ALLELE; AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GREECE; HAPLOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; TREATMENT DURATION; AGED; BLOOD; DRUG ADMINISTRATION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ALLELES; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; HAPLOTYPES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; SIMVASTATIN;

EID: 84903385466     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3334-z     Document Type: Article

References (37)

1. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 326:1423-1427 (Pubitemid 36776152)
2. Superko HR, Momary KM, Li Y (2012) Statins personalized. Med Clin North Am 96:123-139
3. Zineh I (2005) HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol 1:191-206
4. Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc 264:71-75 (Pubitemid 20209174)
5. Puccetti L, Acampa M, Auteri A (2007) Pharmacogenetics of statins therapy. Recent Pat Cardiovasc Drug Discov 2:228-236 (Pubitemid 350213805)
6. Rodrigues AC (2010) Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 6:621-632
7. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African- Americans. J Biol Chem 276:35669-35675
8. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804-813 (Pubitemid 34787251)
9. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565 (Pubitemid 37249126)
10. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide- C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440 (Pubitemid 38971233)
11. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522 (Pubitemid 41017600)
12. Tirona RG, Leake BF, Wolkoff AW, Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304:223-228 (Pubitemid 36008932)
13. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439 (Pubitemid 40279945)
14. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M (2006) Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 62:409-415 (Pubitemid 43873712)
15. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T (2008) Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol 64:257-266
16. Chen R, Davydov EV, Sirota M, Butte AJ (2010) Non-synonymous and synonymous coding SNPs show similar likelihood and effect size of human disease association. PLoS One 5:e13574
17. Waldman YY, Tuller T, Keinan A, Ruppin E (2011) Selection for translation efficiency on synonymous polymorphisms in recent human evolution. Genome Biol Evol 3:749-761
18. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statininduced myopathy - a genomewide study. N Engl J Med 359: 789-799
19. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M (2012) The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 92:112-117
20. Weir B (1996) Disequilibrium. In: Sunderland M (ed) Genetic data analysis II. Sinaur Associates, Sunderland, pp 91-139
21. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265 (Pubitemid 40202029)
22. Browning SR, Browning BL (2007) Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 81:1084-1097 (Pubitemid 47580259)
23. NCBI dbSNP Build 137. http://www.ncbinlmnihgov/projects/SNP/snp-refcgi? rs=rs1057868
24. Couvert P,Giral P,Dejager S, Gu J, Huby T, ChapmanMJ,Bruckert E, Carrie A (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9:1217-1227
25. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415-421 (Pubitemid 38534562)
26. Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, Armitage J, Collins R (2012) Impact of common genetic variation on response to simvastatin therapy among 18,705 participants in the Heart Protection Study. Eur Heart J 34:982-992
27. Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD, Samani NJ, Nixon J, Hall AS, Balmforth AJ (2010) Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 study. Circ Cardiovasc Genet 3:276-285
28. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5:352-358
29. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79:419-426
30. Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J, Packard C, Buckley BM, Schaefer EJ (2012) Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 220:413-417
31. Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH (2012) SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in southern Brazilians. Clin Chem Lab Med 50:441-448
32. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, Bernik MM, Bertolami M, Faludi AA, Brion MJ, Carracedo A, Hirata MH, Hirata RD (2012) Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clin Chim Acta 417C:8-11
33. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I (2006) Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Human Genet 51:822-826 (Pubitemid 44386828)
34. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375-380
35. Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, Wang LC, Fan L, Wang A, Zhou HH (2007) SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol 64:346-352 (Pubitemid 47283861)
36. Hu M, Mak VW, Tomlinson B (2012) Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics 22:803-806
37. Niemi M, Pasanen MK, Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181